货号:A391029
同义名:
甲孕酮
/ 17α-Hydroxy-6α-methylprogesterone;U-8840
Medroxyprogesterone 是一种合成的孕激素受体激动剂,具有避孕和激素替代疗法的作用。Medroxyprogesterone 可用于治疗子宫内膜增生、月经紊乱和乳腺癌等疾病的研究。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic version of progesterone with oral activity, acting as a progesterone receptor agonist. It stimulates cell proliferation via the PI3K/Akt signaling pathway and shows a potential inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is considered less potent than that of Medroxyprogesterone acetate[1].[2].[3].[4]. |
体内研究 | When injected subcutaneously at a daily dose of 27.7 μg, Medroxyprogesterone exerts an inhibitory effect on arteriosclerosis in mice but may increase the risk of thrombosis[3]. |
体外研究 | Medroxyprogesterone (10 nM, over 48 hours) enhances Cyclin D1 expression through the PI3K/Akt pathway, promoting cell proliferation in T47D cells[1]. At a concentration of 100 nM for 24 hours, Medroxyprogesterone increases the adherence of monocytes to human umbilical vein endothelial cells (HUVECs) by boosting the expression of adhesion molecules, which could contribute to the development of atherosclerosis[2]. |
Dose | Macaque: 0.5 mg/kg - 2.5 mg/kg[2] (i.m.) Cynomolgus monkey: 25 mg/kg - 100 mg/kg[3] (i.m.) |
Administration | i.m. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03196492 | - | Recruiting | June 14, 2019 | United States, Maryland ... 展开 >> Johns Hopkins Hospital Recruiting Baltimore, Maryland, United States, 21205 Contact: Okonkwo 收起 << | |
NCT00630435 | Menopause | Phase 1 | Completed | - | - |
NCT01607320 | Polycystic Ovarian Syndrome | Not Applicable | Terminated(Over budget, slow r... 展开 >>ecruitment, and personnel change) 收起 << | - | United States, South Carolina ... 展开 >> Greenville Hospital System Greenville, South Carolina, United States, 29605 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.90mL 0.58mL 0.29mL |
14.51mL 2.90mL 1.45mL |
29.03mL 5.81mL 2.90mL |
CAS号 | 520-85-4 |
分子式 | C22H32O3 |
分子量 | 344.488 |
别名 | 甲孕酮 ;17α-Hydroxy-6α-methylprogesterone;U-8840;NSC 27408;MP;U8840 |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry,Room Temperature |
溶解方案 |
DMSO: 50 mg/mL(145.14 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |
IP 2% DMSO+2% Tween80+30% PEG300+water 0.6 mg/mL clear PO 0.5% CMC-Na 62 mg/mL suspension |